China has issued 16 measures to boost inbound tourism and the export of travel services, Travel Daily News reported. The Ministry of Commerce and eight other government departments issued the measures to lift travel-service exports and inbound spending, Travel Daily News reported. The plan groups the 16 measures across seven areas, and medical tourism sits among them.
For the medical travel trade the key line is narrow but plain. Authorities said they intend to build medical tourism clusters and grow high-end services, from health checks to cosmetic work and rehabilitation care.
Medicine written into a tourism blueprint
The plan folds health services into a wider push on brand, transport links and service standards, Travel Daily News reported. Authorities said they would build a national tourism brand under the banner “Hello China” and a one-stop information site for foreign visitors, and would promote traditional Chinese medicine alongside sightseeing and shopping.
Medical tourism is the concrete part. Travel Daily News reported that the Hainan Boao Lecheng pilot zone is set to keep its central role, including a rule that lets its hospitals use certain urgently needed drugs that are approved abroad but not yet cleared on the mainland. That drug rule is the kind of concrete step that moves patients, since it lets a Chinese hospital offer treatments not otherwise available at home.
Service measures run alongside it. The plan calls for more multilingual help at hotels, restaurants, attractions and, the document said, medical sites, along with more interpreters trained in less common languages. Travel Daily News reported that authorities would widen visa-free entry, test e-visas and set up service desks for overseas business visitors at trade fairs to handle money, legal and travel questions.
Transport measures sit in the same set. Travel Daily News reported that airlines would be urged to add cheaper connecting flights with longer stops in China, and that more cross-border trains would run to link regions. The plan also promises better tax refunds for departing tourists and easier card payments for foreign visitors.
The announcement-versus-arrivals gap
A 16-point policy is an announcement, and announcements and arrivals are different things. That distance is where most national medical tourism plans are won or lost, because a cluster named in a document is not the same as a foreign patient in a bed. China has set the blueprint out in unusual detail, which makes the early numbers worth reading more than the language.
Those early numbers are already showing at the provincial level. Travel Daily News reported that Shandong Province has pushed its “Friendly Shandong” inbound brand, staging events in Seoul aimed at South Korean travellers and showing off cities such as Qingdao, Tai’an and Weifang. During the Spring Festival period a charter flight brought 90 visitors from Thailand to Linyi, and a group of 150 arrived in Weihai by ferry from Incheon, the report said.
The provincial forecasts put a figure on the ambition. Shandong’s culture and tourism department expects roughly 200,000 inbound visitors in the first two months of 2026, a projected 25 per cent rise on the year before, Travel Daily News reported. During the Spring Festival holiday alone the province recorded 39,000 inbound tourists, up 37.7 per cent on the previous year, the report said. Those are general tourism figures rather than medical arrivals, and they cover a single province, but they are the first testable output of the wider policy.
What the medical trade should watch
Medical tourism clusters and the Boao Lecheng drug rule are the parts of the plan that bear directly on patient flows, and neither will show its worth in a policy document. The wider Chinese push has already produced concrete moves elsewhere, from Guangzhou’s international medical tourism service centre to a healthcare sector that is growing unevenly across its segments.
Three items are worth tracking, all dated and checkable. Whether Shandong’s 200,000-visitor forecast for early 2026 is met is the first. Whether the Boao Lecheng zone widens its list of approved foreign drugs is the second. Whether any of the promised medical tourism clusters report foreign-patient numbers, rather than plans, before the year is out is the third, and it is the test that separates a 16-point document from a working destination.
